Nouvelles perspectives dans l’immunothérapie des cancers

Bull Cancer. 2018 Dec:105 Suppl 1:S1-S2. doi: 10.1016/S0007-4551(18)30384-9.
[Article in French]

Abstract

Š.

Publication types

  • Editorial
  • Introductory Journal Article

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological / therapeutic use
  • B7-H1 Antigen / antagonists & inhibitors
  • B7-H1 Antigen / immunology
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / immunology
  • Humans
  • Immunologic Surveillance
  • Immunotherapy / methods*
  • Ipilimumab / therapeutic use
  • Neoplasms / therapy*
  • Nobel Prize
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • CD274 protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Ipilimumab
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • tremelimumab